- Title
- Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
- Creators
- Courtney D. DiNardo - The University of Texas MD Anderson Cancer CenterGail J. Roboz - Weill Cornell MedicineJustin M. Watts - University of MiamiYazan F. Madanat - Southwestern Medical CenterGabrielle T. Prince - Johns Hopkins HospitalPraneeth Baratam - Medical University of South CarolinaStéphane de Botton - Institut Gustave RoussyAnthony Stein - City Of Hope National Medical CenterJames M. Foran - Mayo Clinic in FloridaMartha L. Arellano - Emory UniversityDavid A. Sallman - Moffitt Cancer CenterMohammad Hossain - Servier Pharmaceuticals, LLC, Boston, MA, United StatesDylan M. Marchione - Servier Pharmaceuticals, LLC, Boston, MA, United StatesXiaofei Bai - Servier Pharmaceuticals, LLC, Boston, MA, United StatesPrapti A. Patel - ServierStephanie M. Kapsalis - ServierGuillermo Garcia-Manero - The University of Texas MD Anderson Cancer CenterAmir T. Fathi - Massachusetts General Hospital
- Publication Details
- Blood advances, Vol.8(15), pp.4209-4220
- Number of pages
- 12
- Grant note
- Agios Pharmaceuticals (http://data.elsevier.com/vocabulary/SciValFunders/100016471) V Foundation Lloyd Family Servier (501100011725) BT Group (501100000577)
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- PMID
- 38640348
- Record Identifier
- 991032796160702976
Journal article
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
Blood advances, Vol.8(15), pp.4209-4220
2024-08-13
PMID: 38640348
Metrics
1 Record Views